D. Goldberg, I. C. Ditah, and K. Saeian, Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation, Gastroenterology, vol.152, issue.5, pp.1090-1099, 2017.

, Snapshot, 2017.

C. Welsch, A. Jesudian, S. Zeuzem, and I. Jacobson, New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives, Gut, vol.61, issue.1, pp.36-46, 2012.

S. Zeuzem, R. Ghalib, and K. R. Reddy, Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial, Annals of Internal Medicine, vol.163, issue.1, pp.1-13, 2015.

K. A. Forde, O. Tanapanpanit, and K. R. Reddy, Hepatitis B and C in African Americans: Current status and continued challenges, Clinical Gastroenterology and Hepatology, vol.12, issue.5, pp.738-748, 2014.

M. Lemoine, S. Nayagam, and M. Thursz, Viral hepatitis in resource-limited countries and access to antiviral therapies: Current and future challenges, Future Virology, vol.8, issue.4, pp.371-380, 2013.

A. Azofeifa, M. E. Mattson, G. Schauer, T. Mcafee, A. Grant et al., National Estimates of Marijuana Use and Related Indicators -National Survey on Drug Use and Health, MMWR Surveillance Summaries, vol.65, issue.11, pp.1-28, 2002.

E. Gabbay, Y. Avraham, Y. Ilan, E. Israeli, and E. M. Berry, Endocannabinoids and liver disease -Review, Liver International, vol.25, issue.5, pp.921-926, 2005.

E. Patsenker, P. Sachse, and A. Chicca, Elevated levels of endocannabinoids in chronic hepatitis c may modulate cellular immune response and hepatic stellate cell activation, International Journal of Molecular Sciences, vol.16, issue.4, pp.7057-7076, 2015.

A. C. Adejumo, S. Alliu, and T. O. Ajayi, Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study, PLoS ONE, vol.12, issue.4, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01538556

A. C. Adejumo, T. O. Ajayi, and O. M. Adegbala, Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease, Liver International, 2018.
URL : https://hal.archives-ouvertes.fr/pasteur-01854633

C. Hézode, F. Roudot-thoraval, and S. Nguyen, Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C, Hepatology, vol.42, issue.1, pp.63-71, 2005.

C. Hézode, E. S. Zafrani, and F. Roudot-thoraval, Daily cannabis Use: a novel risk factor of steatosis severity in patients with chronic hepatitis C, Gastroenterology, vol.134, issue.2, pp.432-439, 2008.

J. H. Ishida, M. G. Peters, and C. Jin, Influence of Cannabis Use on Severity of Hepatitis C Disease, Clinical Gastroenterology and Hepatology, vol.6, issue.1, pp.69-75, 2008.

L. Brunet, E. E. Moodie, and K. Rollet, Marijuana smoking does not accelerate progression of liver disease in HIVhepatitis C coinfection: A longitudinal Cohort analysis, Clinical Infectious Diseases, vol.57, issue.5, pp.663-670, 2013.

T. Liu, G. T. Howell, L. Turner, K. Corace, G. Garber et al., Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes, Canadian Journal of Gastroenterology and Hepatology, vol.28, 2014.

E. Kelly, J. Dodge, and M. Sarkar, Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/ Hepatitis C Virus-coinfected Women, Clin Infect Dis, vol.63, issue.4, pp.512-518, 2016.

S. Nordmann, A. Vilotitch, and P. Roux, Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH), Journal of Viral Hepatitis, vol.25, issue.2, pp.171-179, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02146848

H. Lowe, N. Toyang, and W. Mclaughlin, Potential of cannabidiol for the treatment of viral hepatitis, Pharmacognosy Research, vol.9, issue.1, pp.116-118, 2017.

, Citations for HCUP Databases and Tools, 2017.

Z. M. Younossi, M. Otgonsuren, and L. Henry, Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States, Journal of Viral Hepatitis, vol.22, issue.2, pp.137-145, 2015.

A. N. Ananthakrishnan, E. L. Mcginley, J. Fangman, and K. Saeian, Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV, Journal of Viral Hepatitis, vol.17, issue.10, pp.720-729, 2010.

R. Rajbhandari, C. J. Danford, R. T. Chung, and A. , HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease, Alimentary Pharmacology & Therapeutics, vol.41, issue.10, pp.928-938, 2015.

A. J. Kruger, K. Mumtaz, and A. Anaizi, Cirrhosis Is Associated with Increased Mortality in Patients with Diverticulitis: A Nationwide Cross-Sectional Study, Digestive Diseases and Sciences, vol.62, issue.11, pp.3149-3155, 2017.

H. Wu and G. C. Nguyen, Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study, Clinical Gastroenterology and Hepatology, vol.8, issue.9, pp.800-801, 2010.

B. Hammill, GMATCH SAS macro: computerized matching of cases to controls using the greedy matching algorithm with a fixed number of controls per case, 2015.

I. J. Dahabreh, R. C. Sheldrick, and J. K. Paulus, Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes, European Heart Journal, vol.33, issue.15, pp.1893-1901, 2012.

G. D. Kitsios, I. J. Dahabreh, S. Callahan, J. K. Paulus, A. C. Campagna et al., Can We Trust Observational Studies Using Propensity Scores in the Critical Care Literature? A Systematic Comparison with Randomized Clinical Trials, Critical Care Medicine, vol.43, issue.9, pp.1870-1879, 2015.

D. Spiegelman and E. Hertzmark, Easy SAS calculations for risk or prevalence ratios and differences, American Journal of Epidemiology, vol.162, issue.3, pp.199-200, 2005.

D. Van-der-poorten, M. Shahidi, and E. Tay, Hepatitis C Virus Induces the Cannabinoid Receptor 1, PLoS ONE, vol.5, issue.9, p.12841, 2010.

B. Julien, P. Grenard, and F. Teixeira-clerc, Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-755, 2005.

J. Muñoz-luque, J. Ros, and G. Fernández-varo, Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats, The Journal of Pharmacology and Experimental Therapeutics, vol.324, issue.2, pp.475-483, 2008.

F. Borrelli, E. Pagano, and B. Romano, Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabisderived non-psychotropic cannabinoid, Carcinogenesis, vol.35, issue.12, pp.2787-2797, 2014.

M. Guzman, M. J. Duarte, and C. Blázquez, A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, British Journal of Cancer, vol.95, issue.2, pp.197-203, 2006.

N. Vin-raviv, T. Akinyemiju, Q. Meng, S. Sakhuja, and R. Hayward, Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database, Cancer Medicine, vol.6, issue.1, pp.320-329, 2017.

D. L. Sylvestre, B. J. Clements, and Y. Malibu, Cannabis use improves retention and virological outcomes in patients treated for hepatitis C, European Journal of Gastroenterology & Hepatology, vol.18, issue.10, pp.1057-1063, 2006.